S. SEITE, D. MOYAL 
La Roche-Posay Dermatological Laboratories, Asnières, France

INTRODUCTION

METHODS

OBSERVATIONAL STUDY ON PATIENTS WITH ACNE AND AT RISK OF POST-INFLAMMATORY HYPERPIGMENTED LESIONS

Acne is one of the major reasons for dermatological consultation. Post-inflammatory hyperpigmentation (PIH)
is sometimes associated with inflammatory lesions. The aim of this observational study was to evaluate 
the use of a topical formula containing ingredients (niacinamide, procerad, LHA, piroctone olamine, 
linoleic acid) to reduce acne lesions and PIH, alone or in adjunctive therapy, in patients with mild to 
moderate acne and post-inflammatory hyperpigmented lesions.

This survey included 5232 patients (68.2% female, 31.8% male; mean age 22.9 ± 7 years old) with mild 
(47.9%) to moderate (47.4%) acne and was conducted by private practice dermatologists. Phototypes of 
patients were distributed as 6.7% phototype I, 47.5% phototype II, 38.9% phototype III, and 6.5% phototype IV. 
75.8% of patients showed residual colored marks on the face. At baseline, the dermatologists completed a 
questionnaire concerning the patient profile, an evaluation of clinical acne severity (GEA) and noted the 
treatment regimen prescribed. At the second visit, planned 2 months later, dermatologists re-evaluated 
the acne severity, overall tolerance, reduction of seborrhea and residual colored marks.

The topical skin care product was applied twice a day for 53% of patients, in the morning for 31.7% and in 
the evening for 15.3%. Some patients used the topical skin care product alone (35.6% of patients) and others 
used with the same product in adjunctive therapy (64.4% of patients).  

RESULTS

CONCLUSION
This survey demonstrated that a dermocosmetic product containing lipohydroxy acid, 
salicylic acid, linoleic acid, niacinamide, piroctone olamine and procerad (anti-inflammatory 
and anti-melanin synthesis action) can provide good results in managing acne patients 
with risks of post-inflammatory hyperpigmented lesions,when associated with therapeutic 
treatments or alone for milder acne.

80.1% of patients presented an improvement of their 
acne showing a significant effect (p<0.0001) of the 
skin care product after 2 months.

A significant (p< 0.0001) decrease (-47.3% on
average) of seborrhea was observed after 2 months 
with improvement in 88.4% of patients.

There was a significant decrease (p<0.0001) of the number of 
patients presenting marks at the end of the study.

SKIN CARE PRODUCT IN MONOTHERAPY

Severity of acne (GEA) Seborrhea evolution

10 ▲

▼

9

8

7

6

5

4

3

2

1

0
Initial visit Final visit

L
ev

el
 o

f 
se

b
o

rr
h

ea

4.9 ± 2.1

2.6 ± 1.6

-47,3%

60%

50%

40%

30%

20%

10%

0%
Initial visit Final visit

%
 o

f 
su

b
je

ct
s

8,5

0

36,4

47,9

6,6
0,6

11,1

40,6 39,3

8,3

0,6
0

Mild

Severe
Moderate

Virtually no lesions

Very severe

No lesions

Type of local treatments Type of systemic treatments
20%

15%

10%

5%

0%

%
 o

f 
su

b
je

ct
s

Residual colored marks on the face

There was a significant decrease 
(p<0.0001) of the number of patients 
presenting marks at the end of the study.

SKIN CARE PRODUCT IN ADJUNCTIVE THERAPY

17,2

59.4% of the patients had a local treatment and 19.9% a systemic treatment.

83% of patients presented an improvement of their acne 
showing a significant effect (p<0.0001) of the treatment 
associated with the skin care product after 2 months.

A significant (p<0.0001) decrease (-47.3% on 
average) of seborrhea was observed after 2 months 
with improvement in 91.6% of patients.

▼

10 ▲
9

8

7

6

5

4

3

2

1

0
Initial visit Final visit

L
ev

el
 o

f 
se

b
o

rr
h

ea

4.7 ± 2.1

2.4 ± 1.6

-47,3%

50%

40%

30%

20%

10%

0%
Final visitInitial visit

%
 o

f 
su

b
je

ct
s

15,3

0

36,8

43,1

4,4
0,4

17,6

44,2

32

5,8

0,4 0

Mild

Severe
Moderate

Virtually no lesions

Very severe

No lesions

PO
B +

 Ad
ap

ale
ne

as
so

cia
tio

n

Er
yth

rom
yci

n +
 

Tre
tin

oin
 as

so
cia

tio
n

An
tib

iot
ics

Az
ela

ic a
cid

Re
tin

oid
s

PO
B

Ot
he

r lo
ca

l tr
ea

tm
en

t

15,5

11,8

9,5

7,1

3,3

6

10%

8%

6%

4%

2%

0%

%
 o

f 
su

b
je

ct
s

7,8

Ho
rm

on
al

co
ntr

ace
pti

onCy
cli

ns

An
ti-a

nd
rog

en
s

Zin
c g

luc
on

ate

Ot
he

r s
yst

em
ic 

tre
atm

en
t

4,1

1,5

4,2

Severity of acne (GEA) Seborrhea evolution

The skin care product tolerance was evaluated by the dermatologists as high to excellent for 91.2% of the patients. 
91.1% of the patients were satisfied to very satisfied by the product.

4,5

100%

80%

60%

40%

20%

  0%
Initial visit Final visit

%
 o

f 
su

b
je

ct
s

No residual colored marks 
on the face

Residual colored marks
on the face

76,1

23,9

56,4

43,6

Residual colored marks on the face

100%

80%

60%

40%

20%

0%
Initial visit Final visit

%
 o

f 
su

b
je

ct
s

No residual colored marks 
on the face

Residual colored marks
on the face

83,6

16,4

66,1

33,9


	FC17PosterLaRocheSeiteAcneAndLesions.pdf